/
Kewaunee Scientific Corporation (the "Company") was founded in 1906, incorporated in Michigan in 1941, became publicly-held in 1968, and was reincorporated in Delaware in 1970. Our principal business is the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products.
$38.11
+$0.40 (+1.06%)
EOD Jul 17, 2026
Operating margin is thin at 5.93%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 17.3%, still solid.
ROIC dropped from 16.07% to 12.18%, capital efficiency is deteriorating.
11.8x earnings, 7.7x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$282M
▲ +17.3% YoY
Net Income (TTM)
$10M
▼ -15.7% YoY
Op. Margin
5.93%
▼ -1.5pp YoY
ROIC
12.18%
▼ -3.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$15M
▲ +16.5% YoY
Op. Cash Flow (TTM)
$19M
▲ +26.0% YoY
Net Debt
$21M
Cash & Equiv.
$10M
5Y CAGR: +13.8%
Continue Research
At a P/E of 11.8 and a price-to-free-cash-flow of 7.7, Kewaunee Scientific (KEQU) trades below a two-stage DCF intrinsic value of about $78.46 per share, so at $38.11 the stock looks undervalued (105.9% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Kewaunee Scientific scores 63/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $78.46 per share for KEQU, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $58.85. At today's $38.11, that puts the stock about 105.9% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Kewaunee Scientific scores 63 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 5.9% operating margin and a 12.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. KEQU currently trades below its estimated intrinsic value and scores 63/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.